Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice.
Sakane S, Hikita H, Shirai K, Myojin Y, Sasaki Y, Kudo S, Fukumoto K, Mizutani N, Tahata Y, Makino Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Takehara T. Sakane S, et al. Among authors: shirai k. Cell Mol Gastroenterol Hepatol. 2021;12(5):1683-1699. doi: 10.1016/j.jcmgh.2021.07.008. Epub 2021 Jul 22. Cell Mol Gastroenterol Hepatol. 2021. PMID: 34303881 Free PMC article.
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: shirai k. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: shirai k. Aliment Pharmacol Ther. 2022 Apr;55(8):1061-1062. doi: 10.1111/apt.16862. Aliment Pharmacol Ther. 2022. PMID: 35362133 No abstract available.
Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, Tanaka S, Tahata Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Mita E, Tomonaga T, Takehara T. Shirai K, et al. PLoS One. 2022 Jul 7;17(7):e0271020. doi: 10.1371/journal.pone.0271020. eCollection 2022. PLoS One. 2022. PMID: 35797333 Free PMC article.
Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss.
Sato K, Hikita H, Shigekawa M, Kato S, Sasaki Y, Shinkai K, Fukuoka M, Kudo S, Sato Y, Fukumoto K, Shirai K, Myojin Y, Sakane S, Murai K, Yoshioka T, Nishio A, Kodama T, Sakamori R, Tatsumi T, Takehara T. Sato K, et al. Among authors: shirai k. Cancer Sci. 2022 Dec;113(12):4311-4326. doi: 10.1111/cas.15569. Epub 2022 Oct 12. Cancer Sci. 2022. PMID: 36074525 Free PMC article.
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Shirai K, et al. PLoS One. 2022 Dec 21;17(12):e0279416. doi: 10.1371/journal.pone.0279416. eCollection 2022. PLoS One. 2022. PMID: 36542633 Free PMC article.
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis.
Sato K, Hikita H, Shigekawa M, Soma K, Yamauchi R, Sung J, Kato S, Sasaki Y, Kudo S, Fukumoto K, Shirai K, Murai K, Tahata Y, Yoshioka T, Nishio A, Saito Y, Kodama T, Sasaki Y, Tatsumi T, Takehara T. Sato K, et al. Among authors: shirai k. Sci Rep. 2024 May 26;14(1):12028. doi: 10.1038/s41598-024-62498-x. Sci Rep. 2024. PMID: 38797735 Free PMC article.
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.
Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, Sakane S, Murai K, Sasaki Y, Shirai K, Saito Y, Kodama T, Kakita N, Takahashi H, Toyoda H, Suda G, Morii E, Kojima T, Ebihara T, Shimizu K, Sasaki Y, Tatsumi T, Takehara T. Kumazaki S, et al. Among authors: shirai k. Aliment Pharmacol Ther. 2024 Jun 3. doi: 10.1111/apt.18063. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 38828944
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.
Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, Toyoda H, Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Murai K, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T. Sakane S, et al. Among authors: shirai k. Hepatol Commun. 2024 Jun 3;8(6):e0448. doi: 10.1097/HC9.0000000000000448. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38829196 Free PMC article.
1,216 results